BioStem Life Sciences today announced the buildout of a brand new R&D lab. Situated in the Company's 6,100 sq. Ft., state-of-the-art, FDA registered, cGMP facility, this new lab will support the research and development pipeline for the Company's growing Contract Development and Manufacturing (CDMO) business.
BioStem Technologies, Inc. today announced its attendance at the 2020 Perinatal Stem Cell Society Conference. The event, scheduled to be held at the Leonardo Museum in Salt Lake City, Utah, on March 4-6, 2020, brings together industry leaders and academics who are developing and progressing the science of perinatal tissues and how they contain enormous, untapped life potential to help solve diseases and disorders.
BioStem Technologies, Inc. today announced Henry Van Vurst would be stepping down as the company's Chief Executive Officer and as Chairman of the Board of Directors, effective October 22, 2019. Henry is yielding the position to focus on sales and business development for the company’s life sciences division. The BioStem Board of Directors has elected Jason Matuszewski, a co-founder and longtime member of the executive team, as the company's interim Chief Executive Officer and Chairman, effective October 22, 2019.